Welcome to our dedicated page for Lyra Therapeutics news (Ticker: LYRA), a resource for investors and traders seeking the latest updates and insights on Lyra Therapeutics stock.
Lyra Therapeutics, Inc. (Nasdaq: LYRA) is a clinical-stage biotechnology company whose news flow centers on the development and corporate status of its investigational sinonasal implant LYR-210 for chronic rhinosinusitis (CRS). Company press releases describe LYR-210 as a bioabsorbable implant designed for a simple, in-office procedure and intended to deliver six months of continuous anti-inflammatory therapy, mometasone furoate, to the sinonasal passages for CRS patients who have failed medical management.
News updates from Lyra highlight key milestones in the ENLIGHTEN Phase 3 clinical program, including topline results from the ENLIGHTEN 2 trial. The company has reported that ENLIGHTEN 2 met its primary endpoint in adult CRS patients without nasal polyps, with statistically significant improvements in a composite of the three cardinal symptoms of CRS at week 24, as well as statistically significant gains in key secondary endpoints such as SNOT-22 scores. Additional releases discuss pooled analyses in patients with small nasal polyps and 52-week extension data from ENLIGHTEN 1, which the company describes as supporting a favorable safety profile and durable symptom control.
Investors and observers can also find news about Lyra’s regulatory interactions with the U.S. Food and Drug Administration (FDA), including written feedback and meetings that clarify potential paths toward a New Drug Application for specific CRS populations. Corporate and financial news items cover quarterly and annual results, restructuring charges, workforce reductions, and financing transactions such as a registered direct offering and concurrent private placement of warrants.
More recent corporate updates include announcements that the Board of Directors has decided to suspend further development of LYR-210, cease product development operations, and implement workforce reductions while the company evaluates strategic alternatives. For those tracking LYRA, the news stream provides context on clinical data, regulatory discussions, capital markets activity, and changes in Lyra’s operating plans over time.
Lyra Therapeutics (Nasdaq: LYRA) announced on Jan 12, 2026 that its Board has decided to suspend further development of LYR-210 and to cease product development operations while pursuing strategic alternatives. The company disclosed a workforce reduction affecting its remaining 28 employees, retention of the CEO and CFO as consultants, and engagement of SSG Capital Advisors to assist with strategic options.
Lyra cited positive Phase 3 ENLIGHTEN 2 data from June 2025 but reported about $22.1 million in cash and short-term investments as of Sept 30, 2025, with a cash runway into Q3 2026.
Lyra Therapeutics (Nasdaq: LYRA) reported third quarter 2025 results and a corporate update on Nov 12, 2025. The company plans a new, confirmatory Phase 3 trial of LYR-210 for chronic rhinosinusitis (CRS) without nasal polyps to support an NDA submission and presented positive ENLIGHTEN 2 results at AAO-HNS in Oct 2025.
Key financials: cash $22.1M (Sept 30, 2025), runway into Q3 2026; Q3 net loss $6.0M vs $11.9M prior year; R&D $4.0M, G&A $2.2M; net loss per share $3.38.
Lyra Therapeutics (Nasdaq: LYRA) outlined a clinical plan for LYR-210 after a September 2025 FDA meeting and announced a late-breaking oral presentation of positive Phase 3 ENLIGHTEN 2 results at AAO-HNS on October 13, 2025.
ENLIGHTEN 2 met its primary endpoint with statistically significant improvement in the three-cardinal-symptom composite at week 24 in patients without nasal polyps, met key secondary endpoints in the full population and SNOT-22 at week 24, and showed symptom improvement as early as week 4. LYR-210 was generally well tolerated with a safety profile similar to sham. The implant is designed to deliver six months of continuous local anti-inflammatory therapy.
The FDA confirmed that Lyra must conduct an additional clinical trial before an NDA submission for CRS without nasal polyps; Lyra plans to refine that trial using ENLIGHTEN learnings.
Lyra Therapeutics (NASDAQ:LYRA) reported Q2 2025 financial results and highlighted significant progress with its LYR-210 treatment for chronic rhinosinusitis (CRS). The company announced positive Phase 3 ENLIGHTEN 2 trial results in June 2025, meeting its primary endpoint with statistically significant improvement in cardinal symptoms compared to control.
Key financial metrics include cash position of $29.8 million as of June 30, 2025, and a net loss of $7.4 million for Q2 2025, significantly improved from a $48.1 million loss in Q2 2024. The company secured $5.0 million in financing through a registered direct offering, extending cash runway into Q3 2026.
Operational highlights include reengagement with FDA for potential NDA submission, resumed manufacturing activities, and implementation of a 1-for-50 reverse stock split to regain Nasdaq compliance.
Lyra Therapeutics (NASDAQ:LYRA), a clinical-stage biotech company developing treatments for chronic rhinosinusitis, has announced a $15 million financing through a registered direct offering and concurrent private placement. The deal includes $5 million in upfront proceeds through the sale of 423,372 shares at $11.81 per share, plus warrants that could provide up to $9.8 million in additional proceeds if exercised.
The private placement warrants have an exercise price of $11.56 per share, are immediately exercisable, and expire in 24 months. The company plans to use the proceeds for working capital and development of LYR-210. This financing follows Lyra's recent setback in May 2024, when it failed to meet the primary endpoint in its ENLIGHTEN 1 Phase 3 trial.
Lyra Therapeutics (NASDAQ: LYRA) announced plans to present 52-week Extension Stage results from the ENLIGHTEN 1 Phase 3 study for LYR-210, their lead product candidate for chronic rhinosinusitis (CRS), at COSM 2025. Key findings include: LYR-210's favorable safety profile with no treatment-related serious adverse events through Week 52, durable symptom control after treatment cessation, and improvements in both symptoms and polyp size in crossover patients.
The presentation will take place during poster sessions at the Hyatt Regency New Orleans on May 16-17, 2025. The ENLIGHTEN program comprises two pivotal Phase 3 trials (ENLIGHTEN 1 and 2), each enrolling approximately 180 CRS patients who failed medical management and haven't had prior ethmoid sinus surgery. Results from ENLIGHTEN 2 are expected in Q2 2025.
Lyra Therapeutics (NASDAQ: LYRA) reported its Q1 2025 financial results and provided updates on its ENLIGHTEN pivotal program. The company expects topline results from the ENLIGHTEN 2 Phase 3 trial of LYR-210 for Chronic Rhinosinusitis (CRS) in Q2 2025. The trial includes approximately 180 CRS patients, with an additional ~30 polyp patients expected.
Financial highlights: Cash position of $31.7 million as of March 31, 2025, expected to fund operations into Q1 2026. Q1 2025 net loss was $8.5 million, improved from $22.5 million in Q1 2024. R&D expenses decreased to $4.9 million from $18.2 million year-over-year. The company plans a reverse stock split to maintain Nasdaq listing compliance.
Lyra Therapeutics reported its Q4 and full year 2024 financial results, highlighting the upcoming ENLIGHTEN 2 Phase 3 trial results expected in Q2 2025. The company reported encouraging post-hoc data from the ENLIGHTEN 1 Extension Study in CRS patients with nasal polyps, showing improvements in symptoms and polyp size at 52 weeks.
Financial highlights include cash position of $40.6 million as of December 31, 2024, expected to fund operations into Q1 2026. R&D expenses decreased to $43.8 million in 2024 from $48.0 million in 2023. Net loss for 2024 was $93.4 million compared to $62.7 million in 2023.
The company plans a reverse stock split to maintain Nasdaq listing compliance. FDA discussions have provided clarity on the potential path forward for LYR-210 in CRS with nasal polyps, with alignment on various elements of a potential Phase 3 pivotal study.
Incendia Therapeutics has appointed Bradford Smith as Chief Financial Officer. Smith brings over 30 years of strategic and operational leadership experience in healthcare companies, having previously served as CFO at companies including Homology Medicines, Ocular Therapeutix, and NeuroMetrix. Throughout his career, Smith has raised more than $1 billion in financing. He currently serves as board member and Audit Committee Chair for Lyra Therapeutics and eGenesis. In his new role, Smith will oversee all financial functions, including equity financing, investor relations, and business development, reporting directly to CEO Dr. Wendye Robbins.